PENTAPHARM AG (PENTAPHARM S.A.) (PENTAPHARM LTD.) – Trademark Portfolio

Entity Type: 03

PENTAPHARM AG (PENTAPHARM S.A.) (PENTAPHARM LTD.) holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 5 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. The owner is based in BASLE.

ENGELGASSE 109

BASLE , CH

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

PENTAPHARM AG (PENTAPHARM S.A.) (PENTAPHARM LTD.)'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (5 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

3
Cosmetics & Cleaning (1 filing)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does PENTAPHARM AG (PENTAPHARM S.A.) (PENTAPHARM LTD.) have?

PENTAPHARM AG (PENTAPHARM S.A.) (PENTAPHARM LTD.) has 6 U.S. trademarks filed with the USPTO.

What trademark classes does PENTAPHARM AG (PENTAPHARM S.A.) (PENTAPHARM LTD.) file in?

PENTAPHARM AG (PENTAPHARM S.A.) (PENTAPHARM LTD.) files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What is PENTAPHARM AG (PENTAPHARM S.A.) (PENTAPHARM LTD.)'s trademark registration success rate?

PENTAPHARM AG (PENTAPHARM S.A.) (PENTAPHARM LTD.) has a 0% trademark registration rate, with 0 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.